CAR-T Cell Therapy, Mosunetuzumab, and Polatuzumab for Aggressive Non-Hodgkin Lymphoma
This study is testing a new combination treatment for aggressive non-Hodgkin lymphoma (a type of cancer that starts in white blood cells). The treatment involves CAR-T cell therapy (where your own immune cells are modified to fight cancer), along with two other drugs: Mosunetuzumab and Polatuzumab. Researchers want to see if this combination can shrink tumors. You may be eligible if you are between 18 and 80 years old and have certain types of aggressive non-Hodgkin lymphoma, like diffuse large B cell lymphoma (DLBCL). The main goal is to see how many people have a complete response (meaning the cancer is no longer detectable) after 3 months. This study plans to enroll 22 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 22 participants.
- What's involved
- Participants will receive Mosunetuzumab and Polatuzumab infusions before CAR-T cell therapy, which is also given as an infusion. Lymphodepleting chemotherapy will be given before CAR-T cell therapy. Polatuzumab infusions will continue after CAR-T cell therapy.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome, complete response rate, is measured at 3 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
At a glance
Conditions
NCT05260957
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of Miami
Miami, Floridastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Lazaros Lekakis, MD · PRINCIPAL_INVESTIGATOR · University of Miami
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Complete Response Rate3 Months
Complete Response (CR) rate will be reported as the percentage of participants achieving complete response (CR) to study treatment. Response to therapy will be assessed using Positron Emission Tomography (PET)/ Computerized Tomography (CT) scan following Lugano 2014 criteria (Cheson et al, Journal of Clinical Oncology (JCO), 2014) at 3 months (Day +90) of study treatment. For equivocal PET-CT results, biopsy will be performed after day +90 PET/CT to assess true CR or persistent lymphoma.